Found: 22
Select item for more details and to access through your institution.
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 4, p. 3601, doi. 10.3390/ijms24043601
- By:
- Publication type:
- Article
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 15, p. 7812, doi. 10.3390/ijms22157812
- By:
- Publication type:
- Article
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 19, p. 7427, doi. 10.3390/ijms21197427
- By:
- Publication type:
- Article
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 848, doi. 10.1007/s10637-018-0562-4
- By:
- Publication type:
- Article
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-020-00208-2
- By:
- Publication type:
- Article
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 2138, doi. 10.3390/cancers15072138
- By:
- Publication type:
- Article
Immunological Landscape of HER-2 Positive Breast Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 13, p. N.PAG, doi. 10.3390/cancers14133167
- By:
- Publication type:
- Article
Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2848, doi. 10.3390/cancers13112848
- By:
- Publication type:
- Article
Personalized Medicine: Recent Progress in Cancer Therapy.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 1009, doi. 10.3390/cancers12041009
- By:
- Publication type:
- Article
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.
- Published in:
- Cancers, 2020, v. 12, n. 2, p. 412, doi. 10.3390/cancers12020412
- By:
- Publication type:
- Article
First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.744112
- By:
- Publication type:
- Article
miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker.
- Published in:
- Breast Cancer: Basic & Clinical Research, 2020, p. 1, doi. 10.1177/1178223420977845
- By:
- Publication type:
- Article
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2024, v. 43, n. 1, p. 1, doi. 10.1186/s13046-023-02918-4
- By:
- Publication type:
- Article
miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies.
- Published in:
- Cancer Communications, 2022, v. 42, n. 12, p. 1412, doi. 10.1002/cac2.12352
- By:
- Publication type:
- Article
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1151496
- By:
- Publication type:
- Article
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
- Published in:
- Neuro-Oncology, 2023, v. 25, n. 1, p. 157, doi. 10.1093/neuonc/noac144
- By:
- Publication type:
- Article
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-50056-y
- By:
- Publication type:
- Article
Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.01661
- By:
- Publication type:
- Article
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.
- Published in:
- PLoS ONE, 2017, v. 12, n. 5, p. 1, doi. 10.1371/journal.pone.0177331
- By:
- Publication type:
- Article